This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lucas, M. A. Search for Related Content PubMed PubMed Citation Articles by Lucas, M. A. Social Bookmarking                         What's this?

Prevention of Post-Operative Thrombosis in Peripheral Arteriopathies. Pentoxifylline vs. Conventional Antiaggregants: A Six-Month Randomized Follow-up Study

Cardiovascular Department, San Patricio Clinic, Buenos Aires, Argentina

The patency rate and reocclusion incidence were studied in 97 patients following vascular surgery necessitated by occlusion in the aortoiliac or femoropopliteal regions or both. Forty-nine patients were treated orally with a combination of acetylsalicylic acid and dipyridamole (1050 mg + 150 mg/day) and 48 patients with the haemorheologically active agent pentoxifylline (1200 mg/day, Trental® 400 tds.) for uniform periods of 6 months. Reocclusion occurred in 10 patients receiving ASAD and in 5 patients receiving pentoxifylline. Adverse reactions were recorded in 12 patients with ASAD (discontinuation in 11) and in 3 patients with pentoxifylline (discontinuation in 2). Patency and tolerability rate were significantly superior in those patients treated with pentoxifylline, suggesting that the combination of haemorheological effects with antihaemostaseological and antithrombotic properties offered by pentoxifylline may be of benefit in the prevention of reocclusion after vascular surgery.

Angiology, Vol. 35, No. 7, 443-450 (1984)
DOI: 10.1177/000331978403500707


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Ott, E. Korner, and H. Lechner Hemorheologic Treatment of Cerebral Reversible Ischemic Episodes with Pentoxifylline A Prospective Study Angiology, June 1, 1988; 39(6): 520 - 525. [Abstract] [PDF]

				A. Radmilovic, Z. Boric, T. Naumovic, M. Stamenkovic, and P. Musikic Shunt Thrombosis Prevention in Hemodialysis Patients A Double-Blind, Randomized Study: Pentoxifylline vs Placebo Angiology, July 1, 1987; 38(7): 499 - 506. [Abstract] [PDF]

				A. Deutschinoff and L. Grozdinsky Rheological and Anticoagulant Therapy of Patients with Chronic Peripheral Occlusive Arterial Disease (COAD) Angiology, May 1, 1987; 38(5): 351 - 358. [Abstract] [PDF]

				D. Raithel Prevention of Reocclusion After Prosthetic Bypass Operations in the Femoro-Popliteal Region: A Comparative Study of Pentoxifylline Versus Acetylsalicylic Acid Vascular and Endovascular Surgery, May 1, 1987; 21(3): 208 - 214. [Abstract] [PDF]

				R.V. Manrique and V. Manrique Platelet Resistance to Prostacyclin. Enhancement of the Antiaggregatory Effect of Prostacyclin by Pentoxifylline Angiology, February 1, 1987; 38(2): 101 - 108. [Abstract] [PDF]

				R. H. Schroer Antithrombotic Potential of Pentoxifylline A Hemorheologically Active Drug Angiology, June 1, 1985; 36(6): 387 - 398. [Abstract] [PDF]

				R. Mueller On the Therapy of Disturbances of Blood Fluidity Angiology, April 1, 1985; 36(4): 226 - 234. [Abstract] [PDF]